CNS/Neurology
Search text
Neurodegeneration
36 results
(0.05 seconds)
The Technology: A therapeutic intervention addressing the underlying pathogenesis of neurodegeneration. Preventative therapeutic targeting neurodegeneration.
The compounds described in this technology potentially have less toxicity than other compounds that target neurodegeneration in the TIA1/tau/stress granule pathway. Less toxic compared to other compounds that target neurodegeneration in the TIA1/tau/stress granule pathway.
This technology is a variant, mutant, or modulator of the synaptic chaperon protein Hspa8 which potentiates neurotransmission to suppress spinal muscular atrophy (SMA) phenotypes with further applications in other neurogenerative diseases including Amyotrophic Lateral Sclerosis (ALS) and tau-related dementias.
As such, augmenting Alfy may inhibit or treat protein aggregation diseases, particularly within the context of neurodegeneration. Research model for drug discovery related to neurodegeneration.
A majority of these treatments focus on delaying disease onset and managing disease symptoms rather than addressing the biological causes of neurodegeneration.
There is a clear need for disease-modifying therapeutics that target the underlying mechanisms of synaptic dysfunction to prevent neurodegeneration in AD and related disorders. Treatment for AD, Parkinson’s disease, Huntington’s disease, and epilepsy. Prevention of neurodegeneration. Diagnostic marker and therapeutic for diseases characterized by synaptic dysfunction. Research tool for understanding synaptic function and neurodegeneration.
This technology is a FRET-based drug screening tool that identifies TIA1 inhibitors that can potentially limit neurodegeneration across a range of neurological disorders.
Predict dementia/neurodegeneration using driving data.
Multi-organ system model for studying various disease mechanisms (i.e. cancer, neurodegeneration).
Ferroptosis is a recently discovered form of regulated cell death that underlies various disease states, including cancer and neurodegeneration.
This technology is a method to treat Alzheimer’s disease by reducing the level of the cellular biomarker APP-C99.
This technology includes two chemical compounds that are phosphodiesterase type 5 (PDE5) inhibitors with a benzonaphthyridine derivative chemical scaffold that has not previously been used to treat Alzheimer’s disease or other conditions involving phosphodiesterase PDE5 function.
This technology uses peptides secreted by engineered bacteria to reduce virulence of Fusobacterium nucleatum.
Lysosomal phospholipase A2 to study and treat bis(monoacylglycero)phosphate-related disorders
CU23186
This technology is an enzyme that is involved in synthesizing a precursor to bis(monoacylglycero)phosphate (BMP) and can be used to modulate BMP levels and treat BMP-related disorders.
This technology is a drug treatment for Parkinson’s disease and other disorders involving the serotonin 2A receptor.